調査・レポート
2026年9月1日•1分で読めます
Lung Cancer 5‑Year Survival in Korea Jumps to 42.5% Amid EGFR‑TKI Advances
Korea’s 5‑year lung cancer survival rate rose to 42.5% in 2023, driven by targeted therapies and the 10‑year anniversary of third‑gen EGFR‑TKI Tagrisso.
調査・レポート
2026年8月31日•1分で読めます
Hanmi Pharm Pushes Belvarafenib into Phase 2 for NRAS‑Mutant Melanoma
Hanmi Pharm is developing Belvarafenib, the first oral targeted therapy for NRAS‑mutant melanoma, now in Phase 2 with a goal of conditional approval by 2028.
調査・レポート
2026年8月30日•1分で読めます
Targeted Therapies Transform Atopic Dermatitis Treatment
Emerging targeted drugs are shifting atopic dermatitis care from symptom control to broader quality‑of‑life improvements.